Share
Publications
-
12 November 2012 /Prices and reimbursement
-
15 July 2005 /Prices and reimbursement
-
23 April 2010 /Prices and reimbursement
-
23 March 2011 /Prices and reimbursement
Annual report of the Reimbursement Committee 2010
In 2010, the Reimbursement Committee reviewed 20 applications for general reimbursement and 1719 applications for individual reimbursement.
-
12 April 2007 /Prices and reimbursement
Applications for individual reimbursement of medicinal products in 2006
In 2006, the Danish Medicines Agency reviewed some 106.700 applications for single reimbursement (down 4% on 2005), apporx. 14.600 applications for reimbursement for the chronically ill (down 37 % on 2005), approx. 9.200 applications for reimbursement for the terminally ill (same level as in 2005) and approx. 2.700 applications for increased reimbursement (same level as in 2005, cf. table 1 below).
-
16 March 2006 /Prices and reimbursement
Changed consumption of hormones for menopausal women
The quantity consumption of hormones by women with menopausal discomfort has fallen drastically after announcements of increased risk of breast cancer. This is the finding of a consumption analysis performed by the Danish Medicines Agency on the basis of data from the Register of Medicinal Product Statistics.
-
15 December 2009 /Prices and reimbursement
Considerable increase in consumption of antidiabetic drugs from 1999 to 2008 in Denmark
The number of people in Denmark being diagnosed with diabetes has soared for the past many years, and the same can be said for the sums spent on treatment and medicines for antidiabetics.
-
12 October 2006 /Prices and reimbursement
Consumption of antibiotics 2000 – 2005
The past years' development of the consumption of antibiotics has shown that the consumption has increased greatly for several broad-spectrum products. The reason for this may be the increasing extent of prescriptions of broad-spectrum products for infections not requiring such treatment.
-
11 June 2004 /Prices and reimbursement
Consumption of antidepressants in Denmark in the primary health sector in the period 1994-2003
Antidepressant is the designation for medicinal products for depression. At some point in life, approxiamtely 15 per cent of the Danish population will be diagnosed with depression (The Danish Medicinal Product catalogue 2003) - women twice as often as men.
-
25 January 2005 /Prices and reimbursement
Consumption of antipsychotics in Denmark among the elderly
The Danish consumption of antipsychotics among elderly people aged 65 years or above is studied for the period 1996 and 1999-2003. The number of elderly people aged 65 years or above treated with antipsychotics has fallen, whereas the quantity consumption has risen.
-
02 June 2006 /Prices and reimbursement
Consumption of benzodiazepines and benzodiazepine related drugs (cyclopyrrolones)
During the 4th quarter 2003 it was decided that a range of initiatives were to be launched with the purpose of maintaining and strengthening the current tendency of a total decreasing consumption of benzodiazepines (sleeping medicine, tranquilisers and anti-anxiety agents) as well as cyclopyrrolones.
-
12 February 2007 /Prices and reimbursement
Consumption of NSAID in 2005
In 2005, approximately 15 per cent of the Danish population bought NSAID on prescription (approximately 830.000 persons). This figure covers persons undergoing both long-term and short-term treatment, for example person with chronic arthritis diseases or persons with an isolated need, for instance in connection with sports injuries.
-
29 October 2004 /Prices and reimbursement
Consumption of strong analgesics (opioids) in the primary sector Denmark 1999-2003
The study describes the development of the use of strong analgesics (opiods incl. codeine) from 1999 to 2003 in the primary sector. The quantity consumption of opiods has increased by 25.1 per cent during this period from 18.6 DDD/1.000 inhabitants/day in 1999 to 23.2 DDD/1.000 inhabitants/day in 2003.
-
17 February 2005 | Updated 04 November 2011 /Prices and reimbursement
Decreasing consumption of Zyprexa®
The consumption of the antipsychotic medicinal product Zyprexa® decreased during 2004. The decrease in consumption has taken place following EMEA's announcement in March 2004 about a heightened risk of death and brain haemorrhage from treating elderly dementia patients with Zyprexa®.
-
29 October 2004 /Prices and reimbursement
Development of benzodiazepine consumption in Denmark 1996-2003
The benzodiazepine consumption has declined over many years, and this development continues in 2003. During the 8-year study period, the consumption of benzodiazepines as sleeping medicine and sedatives halved from 30.8 to 15.4 DDD/1.000 inhabitants/day
-
28 February 2005 /Prices and reimbursement
-
25 September 2007 /Prices and reimbursement
Dose dispensing in the primary health sector - the first six months of 2007
During the first six months of 2007, 36,962 people had their medicinal products dose dispensed. Elderly women constitute the majority of this group. The consumption of dose dispensed medicinal products accounted for 2.0 percent of the total consumption of medicinal products during the first six months of 2007.
-
23 February 2006 /Prices and reimbursement
Dose dispensing in the primary health sector - the last 6 months of 2005
During the first 6 months of 2005, approximately 26.000 people had their medicinal products dose dispensed. Elderly women constitute the main part of this group. The consumption of dose dispensed medicinal products amounts to 1.6 per cent of the total consumption of medicinal products during the first 6 months of 2005.
-
19 June 2007 /Prices and reimbursement
Dose dispensing in the primary health sector - the last 6 months of 2006
During the last 6 months of 2006, apporximately 35.000 people had their medicinal products dose dispensed. Elderly women constitute the main part of this group. The consumption of dose dispensed medicinal products amounts to 2.0 per cent of the total consumption of medicinal products during the last 6 months of 2006.
-
13 July 2009 | Updated 27 August 2009 /Prices and reimbursement
Effective effort against the excessive use of benzodiazepines in Denmark
A long-term use of sleeping medicine and anti-anxiety drugs of the benzodiazepine type should be avoided, as it can lead to addiction, dizziness, memory impairment and concentration difficulties, as well as an increased risk of falling. Throough the years, many political health care initiatives have therefore been launched in order to reduce the consumption of these medicines.
-
06 January 2011 /Prices and reimbursement
Elderly people’s consumption of medicinal products
Elderly people's consumption of medicinal products is increasing. Regarding all medicine consumers over the age of 64, the sale measured in DKK and defined daily doses has generally increased from 1999 to 2001.
-
31 July 2006 /Prices and reimbursement
Examination of single reimbursement for medicinal products
On behalf of Merck Sharp & Dohme (MSD), Tranberg Marketing Rekommandation has examined general practitioners' knowledge, experience and attitude to single reimbursement for medicine ("Praktiserende lægers kendskab, erfaring og holdning til enkelttilskud til medicin"). The examination is based on telephone interviews with 282 general practitioners.
-
01 April 2003 /Prices and reimbursement
Hoarding of medicinal products in the need-dependent reimbursement system
This analysis indicates that hoarding is a problem within the need-dependent reimbursement system. Among medicine users with expenses exceeding DKK 510 within a reimbursement year, hoarding is estimated to constitute approximately 2 per cent of the users' reimbursable medicine expenses.
-
19 July 2007 /Prices and reimbursement
Increase in consumption of urinary antispasmodics
More and more people buy the so-called urinary antispamodics for treatment of overactive bladder. In four years, consumption has increased by 58.6 percent from 19.476 persons in 2001 to 30.899 in 2005. The increased consumption of this type of medicinal products is specifically centred on the more expensive products, which has led to a considerable increase in the sale of these products.
-
22 May 2003 /Prices and reimbursement
Investigation of pharmacies' dispense practice
The purpose of the present investigation is to shed light on the variations in pharmaceutical companies' market shares at individual pharmacies and to investigate whether these differences mean that the dispense practice is inappropriate or expensive.
-
15 April 2011 | Updated 05 July 2011 /Prices and reimbursement
Monitor the trends in consumption of cardiovascular medicines
We monitor the trends in consumption of cardiovascular medicines (blood pressure medicines) in connection with the reimbursement changes for cardiovascular medicines of 13 July 2009 and 15 November 2010.
-
25 January 2012 /Prices and reimbursement
Monitor the trends in consumption of drugs for acid-related disorders
The Danish Medicines Agency monitors the consumption of drugs for acid-related disorders (drugs for heartburn, sour eructation and ulcer) in connection with the removal of the reimbursement for a number of these drugs on 15 November 2010.
-
09 October 2003 /Prices and reimbursement
Note on products for Alzheimer's disease in Denmark
This study sheds light on the development of the use of medicinal products for Alzheimer's disease during the period September 1997 until April 2003. Four medicinal products are used for treating Alzheimer's disease - 3 cholinesterase inhibitors (Aricept®, Exelon® and Reminyl®) and a glutamine
-
28 April 2009 /Prices and reimbursement
-
31 March 2010 /Prices and reimbursement
-
14 June 2011 /Prices and reimbursement
Number of applications for individual reimbursement of medicines in 2010
In 2010, we reached decisions in a total of 144,324 individual reimbursement applications against 138,714 in 2009, corresponding to an increase of 4 %. The figure breaks down to approx. 96,000 applications for single reimbursement (about 3 % fewer than in 2009), approx. 34,000 applications for reimbursement for the chronically ill (about 30 % more than in 2009), approx. 12,000 applications for reimbursement for the terminally ill (about 7 % more than in 2009) and approx. 2,800 applications for increased reimbursement (about 14 % more than in 2009).
-
02 March 2012 /Prices and reimbursement
Number of applications for individual reimbursement of medicines in 2011
In 2011, the Danish Medicines Agency (now the Danish National Board of Health) reviewed approx. 103,000 applications for single reimbursement (about 7 % more than in 2010), approx. 26,000 applications for reimbursement for the chronically ill (about 30 % less than in 2010), approx. 12,000 applications for reimbursement for the terminally ill (about 3 % more than in 2010) and approx. 2,500 applications for increased reimbursement (about 12 % less than in 2010), cf. table 1.
-
01 February 2005 /Prices and reimbursement
Potentially inappropriate prescription of the asthma product Singulair®
The asthma product Singulair® was put on the Danish market in February 1998 and became eligible for general reimbursement 13 July 1998. The medicinal product is recommended as a supplement for treatment of mild to moderate asthma as well as for exercise-induced asthma.
-
06 June 2006 /Prices and reimbursement
-
01 December 2009 /Prices and reimbursement
Sale of dose dispensed medicine in the primary Danish health sector 2004-2008
Dose dispensing was launched in Denmark in 2002, and the use of dose dispensing has increased since then. Dose dispensing is used by all age groups, but the share of users increases with age, and women more frequently use dose dispensed medicine than men.
-
17 June 2009 /Prices and reimbursement
Sale of liberalised OTC medicines from 2001-2007
The liberalisation of over-the-counter products (OTC medicines) may have contributed to an increase in the sale of smoking cessation products in the period from 2001-2007. With regard to the remaining medicinal products, there is nothing to suggest that the sale in general sales outlets has led to increased consumption.
-
06 July 2004 /Prices and reimbursement
Sale of medicinal products for the treatment of erectile dysfunction
This study sheds light on the development of the use of medicinal products for the treatment of erectile dysfunction in the period between 1998 and 2003. In october 1998, Viagra® was put on the market, and since then the sale of medicinal products for the treatment of erectile dysfunction has increased rapidly.
-
13 July 2005 /Prices and reimbursement
Sales of liberalised non-prescription medicinal products: 2001 - the first three months of 2005
For the main part of liberalised medicinal products, the liberalisation, and thereby the easier access to buy the medicinal products, has hardly affected the consumption development. One exception is the sale of anti-smoking products. Since the liberalisation on 1 October 2001, sales have increased by 48 per cent.
-
30 July 2007 /Prices and reimbursement
The consumption of benzodiazepines and benzodiazepine related drugs
In the 4th quarter 2003, it was decided to launch a range of initiatives with the aim of maintaining and strengthening the trend at the time with an overall decreasing consumption of benzodiazepines and benzodiazepine related drugs. The consumption development over the past five years is shown below.
-
30 September 2003 /Prices and reimbursement
The sale of the anti-cholinergic agent Spiriva®
Since Spiriva® was introduced on the market in the second quarter of 2002, there has been a great increase in both the consumption and prevalence of the agent among the elderly.
-
17 August 2004 /Prices and reimbursement
Treatment of blood clots with platelet function inhibitors
The rising expenses of platelet function inhibitors are caused by several factors. In general, the consumption of these medicinal products is increasing, which is due to the fact that, both in relative and absolute terms, more people start treatment with platelet function inhibitors.
-
17 June 2009 /Prices and reimbursement
Use of prescription weight-loss products from 2003-2007
In recent years, the number of persons treated with prescription-only weight-loss products has increased, however, the total number of persons receiving treatment is lower than before 2002. The weight-loss products are primarily used by women aged between 35-55. In 2007, the number of users was affected by seasonal variations, which are more pronounced if we exclude persons who at the same time receive other medicines associated with overweight.
